Abstract
Apoptosis plays an important role in development, growth, differentiation, altered gravity conditions, tissue homeostasis, immune defense, and cancer. It can be initiated by external signals via death receptors, but may also emerge from mitochondria. Today most of the key players in cellular apoptosis regulation are identified and can be targeted by therapeutic strategies. In this review we focus on recent development of drugs, which interfere with apoptosis and are currently used or tested for treatment of breast cancer. These novel agents include those targeting the extrinsic pathway such as Fas, tumor necrosis factor – alpha and tumor necrosis factor related apoptosisinducing ligand, as well as drugs targeting the intrinsic Bcl-2 family pathway, or drugs inhibiting repair enzymes such as Poly (ADPribose) polymerase (PARP) inhibitors. Their function will be explained, their role in tumor biology and actual clinical studies will be discussed.
Keywords: Apoptosis, breast cancer, BCL-2, Fas, TNF-alpha, TRAIL, PARP inhibitors
Current Pharmaceutical Design
Title: Drugs Interfering with Apoptosis in Breast Cancer
Volume: 17 Issue: 3
Author(s): Daniela Grimm, Markus Wehland, Jessica Pietsch, Manfred Infanger and Johann Bauer
Affiliation:
Keywords: Apoptosis, breast cancer, BCL-2, Fas, TNF-alpha, TRAIL, PARP inhibitors
Abstract: Apoptosis plays an important role in development, growth, differentiation, altered gravity conditions, tissue homeostasis, immune defense, and cancer. It can be initiated by external signals via death receptors, but may also emerge from mitochondria. Today most of the key players in cellular apoptosis regulation are identified and can be targeted by therapeutic strategies. In this review we focus on recent development of drugs, which interfere with apoptosis and are currently used or tested for treatment of breast cancer. These novel agents include those targeting the extrinsic pathway such as Fas, tumor necrosis factor – alpha and tumor necrosis factor related apoptosisinducing ligand, as well as drugs targeting the intrinsic Bcl-2 family pathway, or drugs inhibiting repair enzymes such as Poly (ADPribose) polymerase (PARP) inhibitors. Their function will be explained, their role in tumor biology and actual clinical studies will be discussed.
Export Options
About this article
Cite this article as:
Grimm Daniela, Wehland Markus, Pietsch Jessica, Infanger Manfred and Bauer Johann, Drugs Interfering with Apoptosis in Breast Cancer, Current Pharmaceutical Design 2011; 17 (3) . https://dx.doi.org/10.2174/138161211795049723
DOI https://dx.doi.org/10.2174/138161211795049723 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Current Bioactive Compounds Anti-miRNA-23a Oligonucleotide Suppresses Glioma Cells Growth by Targeting Apoptotic Protease Activating Factor-1
Current Pharmaceutical Design Neuropilin-1 (NRP-1) and Magnetic Nanoparticles, a Potential Combination for Diagnosis and Therapy of Gliomas
Current Pharmaceutical Design Antibody Targeting of TGF-β in Cancer Patients
Current Pharmaceutical Biotechnology Role of Antioxidants, Essential Fatty Acids, Carnitine, Vitamins, Phytochemicals and Trace Elements in the Treatment of Diabetes Mellitus and its Chronic Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis, and <i>In-silico</i> Studies of Indole-chalcone Derivatives Targeting Estrogen Receptor Alpha (ER-α) for Breast Cancer
Current Computer-Aided Drug Design Radiolabeled Protein-inhibitor Peptides with Rapid Clinical Translation towards Imaging and Therapy
Current Medicinal Chemistry Chalcones in Cancer: Understanding their Role in Terms of QSAR. II Part
Mini-Reviews in Medicinal Chemistry Dietary Fish Oil Reduces Colon Cancer Risk
Current Organic Chemistry Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) – a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Sugar Based Biopolymers in Nanomedicine; New Emerging Era for Cancer Imaging and Therapy
Current Topics in Medicinal Chemistry Glycosylation of Tetraspanin Tspan-1 at Four Distinct Sites Promotes Its Transition Through the Endoplasmic Reticulum
Protein & Peptide Letters Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Editorial (Hot Topic: Vitamin D and Cancer: Current Evidence and Future Perspective)
Anti-Cancer Agents in Medicinal Chemistry Beauvericin, A Fusarium Mycotoxin: Anticancer Activity, Mechanisms, and Human Exposure Risk Assessment
Mini-Reviews in Medicinal Chemistry Pattern of Medication Use Among Older Inpatients in Seven Hospitals in Italy: Results from the Criteria to Assess Appropriate Medication Use Among Elderly Complex Patients (CRIME) Project
Current Drug Safety The Prolyl-Aminodipeptidases and their Inhibitors as Therapeutic Targets for Fibrogenic Disorders
Mini-Reviews in Medicinal Chemistry The Multiple Roles of Vitamin D in Human Health. A Mini-Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging